Celcuity Appoints David Gryska To Its Board Of Directors
Key Highlights
- ➤David W. Gryska appointed to Celcuity’s (CELC) Board of Directors
- ➤Gryska brings over 35 years of life sciences strategic and financial leadership
- ➤Celcuity (CELC) transitions into a commercial-stage company following REVTORPYK FDA approval
- ➤REVTORPYK commercial launch targets advanced breast cancer
- ➤Gryska previously served as CFO of Incyte and Celgene
Expert Statements
Brian Sullivan, Chief Executive Officer and co-founder of Celcuity
“On the heels of our first FDA approval for REVTORPYK™, we are pleased to welcome David to our Board of Directors as we transition into a commercial-stage company.”
Brian Sullivan, Chief Executive Officer and co-founder of Celcuity
“David's extensive experience as a Chief Financial Officer and board member of a number of pharmaceutical companies, through periods of significant clinical development and commercial growth makes him an outstanding addition to our Board.”
Brian Sullivan, Chief Executive Officer and co-founder of Celcuity
“We are confident he will provide valuable expertise as we execute the launch of REVTORPYK, advance our clinical development programs, and continue building the capabilities needed to support long-term growth.”
David W. Gryska, Director of Celcuity
“Celcuity is entering an exciting new chapter, with the company poised for significant growth over the next few years following the FDA approval and commercial launch of REVTORPYK in advanced breast cancer.”
David W. Gryska, Director of Celcuity
“I look forward to supporting Brian and Celcuity’s experienced leadership team as we build on this momentum, advance gedatolisib in additional solid tumor indications, and work to bring meaningful benefits to more patients.”
MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced the appointment of David W. Gryska to its Board of Directors. Mr. Gryska is a seasoned executive who brings over 35 years of strategic and financial leadership experience in the life sciences industry to Celcuity, including advising early-stage biotechnology companies.
“On the heels of our first FDA approval for REVTORPYK™, we are pleased to welcome David to our Board of Directors as we transition into a commercial-stage company,” said Brian Sullivan, Chief Executive Officer and co-founder of Celcuity. “David's extensive experience as a Chief Financial Officer and board member of a number of pharmaceutical companies, through periods of significant clinical development and commercial growth makes him an outstanding addition to our Board. We are confident he will provide valuable expertise as we execute the launch of REVTORPYK, advance our clinical development programs, and continue building the capabilities needed to support long-term growth.”
Get started
Create a free account to read the full story.